Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
Papp, K.A., Menter, M.A., Abe, M., Elewski, B., Feldman, S.R., Gottlieb, A.B., Langley, R., Luger, T., Thaci, D., Buonanno, M., Gupta, P., Proulx, J., Lan, S., Wolk, R.
Published in British journal of dermatology (1951) (01.10.2015)
Published in British journal of dermatology (1951) (01.10.2015)
Get full text
Journal Article
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
Papp, K.A., Menter, M.A., Raman, M., Disch, D., Schlichting, D.E., Gaich, C., Macias, W., Zhang, X., Janes, J.M.
Published in British journal of dermatology (1951) (01.06.2016)
Published in British journal of dermatology (1951) (01.06.2016)
Get full text
Journal Article
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up
Lebwohl, M., Deodhar, A., Griffiths, C.E.M., Menter, M.A., Poddubnyy, D., Bao, W., Jehl, V., Marfo, K., Primatesta, P., Shete, A., Trivedi, V., Mease, P.J.
Published in British journal of dermatology (1951) (01.11.2021)
Published in British journal of dermatology (1951) (01.11.2021)
Get full text
Journal Article
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2022)
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2022)
Get full text
Journal Article
Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
Menter, M.A., Murakawa, G.J., Glover, H., Mendelsohn, A.M., Parno, J., Rozzo, S.J., Davidson, D., Gupta, A.K.
Published in Journal of the European Academy of Dermatology and Venereology (01.12.2020)
Published in Journal of the European Academy of Dermatology and Venereology (01.12.2020)
Get full text
Journal Article